Structural basis for inhibiting β-amyloid oligomerization by a non-coded β-breaker-substituted endomorphin analogue

Anat Frydman-Marom, Marino Convertino, Riccardo Pellarin, Ayala Lampel, Ronit Shaltiel-Karyo, Daniel Segal, Amedeo Caflisch, Deborah E. Shalev, Ehud Gazit

Research output: Contribution to journalArticlepeer-review

Abstract

The distribution of endomorphins (EM) 1 and 2 in the human brain inversely correlates with cerebral neurodegeneration in Alzheimer's disease (AD), implying a protective role. These endogenous opioid peptides incorporate aromatic residues and a β-breaker motif, as seen in several optimized inhibitors of Aβ aggregation. The activity of native endomorphins was studied, as well as the rationally designed analogue Aib-1, which includes a remarkably efficient β-breaker, α-aminoisobutyric acid (Aib). In vitro and GFP fusion protein assays showed that Aib-1 interacted with Aβ and markedly inhibited the formation of toxic oligomer and fibril growth. Moreover, Aib-1 prevented the toxicity of Aβ toward neuronal PC12 cells and markedly rectified reduced longevity of an AD fly model. Atomistic simulations and NMR-derived solution structures revealed that Aib-1 significantly reduced the propensity of Aβ to aggregate due to multimode interactions including aromatic, hydrophobic, and polar contacts. We suggest that hindering the self-assembly process by interfering with the aromatic core of amyloidogenic peptides may pave the way toward developing therapeutic agents to treat amyloid-associated diseases.

Original languageEnglish
Pages (from-to)1265-1276
Number of pages12
JournalACS Chemical Biology
Volume6
Issue number11
DOIs
StatePublished - 18 Nov 2011

Fingerprint

Dive into the research topics of 'Structural basis for inhibiting β-amyloid oligomerization by a non-coded β-breaker-substituted endomorphin analogue'. Together they form a unique fingerprint.

Cite this